{"id":619,"date":"1999-06-01T12:00:00","date_gmt":"1999-06-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/prophylaktischer-einsatz-von-g-csf-in-der-tumortherapie-welche-dosis-welche-indikation"},"modified":"2022-03-17T14:09:11","modified_gmt":"2022-03-17T13:09:11","slug":"prophylaktischer-einsatz-von-g-csf-in-der-tumortherapie-welche-dosis-welche-indikation","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/prophylaktischer-einsatz-von-g-csf-in-der-tumortherapie-welche-dosis-welche-indikation","title":{"rendered":"Prophylaktischer Einsatz von G-CSF in der Tumortherapie: Welche Dosis? Welche Indikation?"},"content":{"rendered":"<p>Zum prophylaktischen Einsatz von Granulozyten-Kolonien-stimulierendem Faktor (G-CSF; Filgrastim = Neupogen, Lenograstim = Granocyte) oder Granulozyten-Makrophagen-Kolonien-stimulierendem Faktor (GM-CSF, Molgramostim = Leucomax) zur Verk\u00fcrzung der Granulozytopenie nach antineoplastischer Chemotherapie liegen seit 1994 Empfehlungen der American Society of Clinical Oncology (ASCO) vor (1, 2). Auf die zahlreichen offenen Fragen (z.B. rationale Indikationsstellung, Beginn, Dauer, Tagesdosis) zum Einsatz von [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zum prophylaktischen Einsatz von Granulozyten-Kolonien-stimulierendem Faktor (G-CSF; Filgrastim = Neupogen, Lenograstim = Granocyte) oder Granulozyten-Makrophagen-Kolonien-stimulierendem Faktor (GM-CSF, Molgramostim = Leucomax) zur Verk\u00fcrzung der Granulozytopenie nach antineoplastischer Chemotherapie liegen seit 1994 Empfehlungen der American Society of Clinical Oncology (ASCO) vor (1, 2). Auf die zahlreichen offenen Fragen (z.B. rationale Indikationsstellung, Beginn, Dauer, Tagesdosis) zum Einsatz von [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1440,139,142,140,1410,262,264],"class_list":["post-619","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-filgrastim","tag-g-csf","tag-granulozyten-kolonien-stimulierender-faktor","tag-lenograstim","tag-polychemotherapie","tag-zytostatika","tag-zytostatische-therapie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=619"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/619\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}